These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 38832423)

  • 41.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
    Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
    Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.
    Davila ML; Brentjens RJ
    Clin Adv Hematol Oncol; 2016 Oct; 14(10):802-808. PubMed ID: 27930631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia.
    Tan Y; Shan L; Zhao L; Deng B; Ling Z; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Tian Z; Zhang Y; Zhang J; Chang AH; Feng X; Pan J
    J Hematol Oncol; 2023 Apr; 16(1):34. PubMed ID: 37020231
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
    Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
    J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
    Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
    Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
    J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. InsT-ALLing CD7 chimeric antigen receptors before transplantation.
    Delgado J
    Br J Haematol; 2024 Jun; 204(6):2155-2156. PubMed ID: 38676290
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
    Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
    [No Abstract]   [Full Text] [Related]  

  • 54. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
    Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
    Front Immunol; 2020; 11():1347. PubMed ID: 32714329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
    Roddie C; Dias J; O'Reilly MA; Abbasian M; Cadinanos-Garai A; Vispute K; Bosshard-Carter L; Mitsikakou M; Mehra V; Roddy H; Hartley JA; Spanswick V; Lowe H; Popova B; Clifton-Hadley L; Wheeler G; Olejnik J; Bloor A; Irvine D; Wood L; Marzolini MAV; Domning S; Farzaneh F; Lowdell MW; Linch DC; Pule MA; Peggs KS
    J Clin Oncol; 2021 Oct; 39(30):3352-3363. PubMed ID: 34464155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
    Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
    Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
    Fousek K; Watanabe J; Joseph SK; George A; An X; Byrd TT; Morris JS; Luong A; Martínez-Paniagua MA; Sanber K; Navai SA; Gad AZ; Salsman VS; Mathew PR; Kim HN; Wagner DL; Brunetti L; Jang A; Baker ML; Varadarajan N; Hegde M; Kim YM; Heisterkamp N; Abdel-Azim H; Ahmed N
    Leukemia; 2021 Jan; 35(1):75-89. PubMed ID: 32205861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.